5th Edelris Symposium on AS-MS in Drug Discovery
To celebrate its 20th anniversary, Edelris is organizing a symposium dedicated to modern drug discovery. It provides an opportunity to reflect on two decades of innovations that offer hope for identifying new therapies for patients. We will discuss the significant progress made on complex targets and explore new therapeutic approaches, such as protein degradation and non-coding RNA targeting.
This anniversary event will feature our 5th Symposium on Affinity Selection-Mass Spectrometry (AS-MS). Over the years, AS-MS has matured into a screening technology for hit identification, especially for challenging targets like membrane proteins, transcription factors, and RNAs. Key contributors from the field will share their latest results and experiences with this technology.
Registrations will be open soon.
Previous events
2024 Edition
The fourth edition of the symposium opened with the presentation of new AS-MS perspectives, introducing CIAS-MS as a new technology offering the possibility to analyze by mass spectrometry, both the protein/ligand complex and its dissociated form. Various technical aspects of screening platforms dedicated to hit identification were discussed. The successes leading to the development of molecular tools to explore new targets were also presented.
2023 Edition
The program focused on the techniques developed by pharma and CRO organizations to implement AS-MS in their drug discovery process. Automated Data Processing was discussed and the synergy with other HTS technologies, particularly DELT, was emphasized.
2022 Edition
The program covered several aspects of AS-MS, featuring recent technological developments and exciting results on hot targets using various chemical matters including ultra-large libraries of peptides.
2021 Edition
The 1st Edelris Symposium highlighted the use of Affinity Selection-Mass Spectrometry (AS-MS) techniques to explore broad chemical spaces – biased collections, natural products, and large libraries.